Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Down 19.7% in February

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 4,485 shares, a drop of 19.7% from the February 12th total of 5,585 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 19,031 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 19,031 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Stock Performance

Shares of MTNB stock traded up $0.00 during midday trading on Friday, hitting $0.64. 7,696 shares of the company were exchanged, compared to its average volume of 16,535. Matinas Biopharma has a 52 week low of $0.47 and a 52 week high of $3.09. The firm has a market capitalization of $4.12 million, a P/E ratio of -0.19 and a beta of 1.32. The firm’s 50 day moving average price is $0.63 and its two-hundred day moving average price is $1.08.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.